Frank Kerrigan

915 total citations
11 papers, 766 citations indexed

About

Frank Kerrigan is a scholar working on Organic Chemistry, Oncology and Molecular Biology. According to data from OpenAlex, Frank Kerrigan has authored 11 papers receiving a total of 766 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Organic Chemistry, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Frank Kerrigan's work include PARP inhibition in cancer therapy (4 papers), Cancer therapeutics and mechanisms (2 papers) and Receptor Mechanisms and Signaling (2 papers). Frank Kerrigan is often cited by papers focused on PARP inhibition in cancer therapy (4 papers), Cancer therapeutics and mechanisms (2 papers) and Receptor Mechanisms and Signaling (2 papers). Frank Kerrigan collaborates with scholars based in United Kingdom. Frank Kerrigan's co-authors include Graeme C.M. Smith, Xiaoling Cockcroft, Niall M.B. Martin, Keith Menear, Sylvie Gomez, Ian T.W. Matthews, Charlotte Knights, Alan Lau, Aaron Cranston and Mark J. O’Connor and has published in prestigious journals such as Journal of Medicinal Chemistry, Tetrahedron Letters and Bioorganic & Medicinal Chemistry Letters.

In The Last Decade

Frank Kerrigan

11 papers receiving 743 citations

Peers

Countries citing papers authored by Frank Kerrigan

Since Specialization

Citations

This map shows the geographic impact of Frank Kerrigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Kerrigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Kerrigan more than expected).

Fields of papers citing papers by Frank Kerrigan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Kerrigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Kerrigan. The network helps show where Frank Kerrigan may publish in the future.

Co-authorship network of co-authors of Frank Kerrigan

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Kerrigan. A scholar is included among the top collaborators of Frank Kerrigan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Kerrigan. Frank Kerrigan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1 2008 ·Journal of Medicinal Chemistry ·Keith Menear, (unknown), (unknown), Xiaoling Cockcroft, (unknown), Aaron Cranston, (unknown), (unknown), (unknown), Sylvie Gomez, (unknown), Frank Kerrigan, Charlotte Knights, Alan Lau, (unknown), Ian T.W. Matthews, Stephen Moore, Mark J. O’Connor, Graeme C.M. Smith, Niall M.B. Martin	483
2	Phthalazinones 2: Optimization and Synthesis of Novel Potent Inhibitors of Poly(ADP‐Ribose)polymerase. 2006 ·ChemInform ·Xiaoling Cockcroft, (unknown), (unknown), (unknown), Frank Kerrigan, (unknown), Niall M.B. Martin, Keith Menear, Graeme C.M. Smith	4
3	Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase 2005 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Xiaoling Cockcroft, (unknown), (unknown), (unknown), (unknown), Sylvie Gomez, (unknown), Frank Kerrigan, Ian T.W. Matthews, Keith Menear, Niall M.B. Martin, Roger F. Newton, (unknown), Graeme C.M. Smith, (unknown), Alan J. Whittle	79
4	Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase 2005 ·Bioorganic & Medicinal Chemistry Letters ·Xiaoling Cockcroft, (unknown), (unknown), (unknown), Frank Kerrigan, (unknown), Niall M.B. Martin, Keith Menear, Graeme C.M. Smith	70
5	N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D₂ Antagonists/5-HT_1A Partial Agonists with Potential as Atypical Antipsychotic Agents 1999 ·Journal of Medicinal Chemistry ·Alan M. Birch, Paul A. Bradley, (unknown), Frank Kerrigan, (unknown)	40
6	Antidepressant patents: 1995 - 1997 1998 ·Expert Opinion on Therapeutic Patents ·Frank Kerrigan	9
7	Synthesis of arylpiperazines via palladium-catalysed aromatic amination reactions of bromoarenes with N-tert-butoxycarbonylpiperazine 1998 ·Tetrahedron Letters ·Frank Kerrigan, Claire Martin, (unknown)	32
8	A New Convenient Synthesis of 1-(3-Hydroxy-4-Methoxyphenyl)Ethane-1,2-Diol (iso-Mhpg) and its Enantiomers 1998 ·Synthetic Communications ·(unknown), Frank Kerrigan	7
9	Synthesis of sibutramine, a novel cyclobutylalkylamine useful in the treatment of obesity, and its major human metabolites 1996 ·Journal of the Chemical Society Perkin Transactions 1 ·(unknown), Frank Kerrigan, Thomas Miller, Graham J. Smith, (unknown)	26
10	Facile synthesis of phosphorus-containing heterocycles 1996 ·Tetrahedron Letters ·E.Andrew Boyd, (unknown), Frank Kerrigan	13
11	Addition reactions of benzo[b] thiophen. Part 3. Addition and ring-opening reactions with phenolic ethers 1982 ·Journal of the Chemical Society Perkin Transactions 1 ·Peter D. Clark, David F. Ewing, Frank Kerrigan, R. M. Scrowston	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact